Гиперфосфатемия при хронической болезни почек

СтатьяМЕД СОВЕТ. 2019; № 16: 78–85. DOI:10.21518/2079-701X-2019-16-78-85

Мартынов С.А.^[1]

Шамхалова М.Ш.^[1]

^[1]"Национальный медицинский исследовательский центр эндокринологии" Минздрава РФ

Гиперфосфатемия при почечной патологии является ключевым фактором развития минеральных и костных нарушений. Она может развиться уже при начальном снижении фильтрационной функции почек и быть предиктором формирования сосудистой кальцификации и повышения риска развития сердечно-сосудистых осложнений у пациентов с хронической болезнью почек, особенно находящихся на лечении программным гемодиализом. Применение кальций-несодержащих фосфорсвязывающих препаратов без риска развития гиперкальциемии позволяет замедлить развитие кальцификации сосудов, сократить частоту неблагоприятных кардиоваскулярных событий и снизить смертность у пациентов с хронической болезнью почек.

гиперфосфатемия

кальций-несодержащие фосфорсвязывающие препараты

севеламер

хроническая болезнь почек

Алюминий

Ацетаты

Белки

Болезнь

Боли

Больные

Время

Гемодиализ

Гидроксиды

Гиперкальциемия

Гиперфосфатемия

Диализ

Железо

Заболеваемость

Кальций

Карбонаты

Кинез

Кишечник

Клетки

Кровь

Лантан

Магний

Москва

Мыши

Образование

Патология

Пептиды

Причинная связь

Риск

Севеламер

Смертность

Фосфаты

Фосфор

Хроническая болезнь

Человек

Ospina C.A.G., Holguin M.C., Escobar D.C., Valencia C.A.R.Importance of hyperposphatemia in chronic kidney disease, how to avoid it and treat it by nutritional measures. Rev Colomb Nefrol. 2017;4(1):24-41. doi: 10.22265/acnef.4.1.270..
DOI: 10.22265/acnef.4.1.270

Hruska K.A., Mathew S., Lund R., Qiu P., Pratt R. Hyperphosphatemia of chronic kidney disease. Kidney Int. 2008;74(2):148-157. doi: 10.1038/ ki.2008.130..
DOI: 10.1038/ ki.2008.130

Prasad N., Bhadauiria. Renal phosphate handling: phisiology. Indian Endocrinol Metab. 2013;17(4):620-227. doi: 10.4103/2230- 8210.113752..
DOI: 10.4103/2230- 8210.113752

Takashi Y., Fukumoto S. FGF23-Klotho axis in CKD. Renal Replacement Therapy. 2016;(2):20. doi 10.1186/s41100-016-0032-4.

Kumar R., Thopsmon R. The regulation of parathyroid hormone secretion. J Amer Soc Nephrol. 2011;22(2):224-224. doi: 10.1681/ ASN.2010020186..
DOI: 10.1681/ ASN.2010020186

Cannata-Andía J.B., Martin K.J. The challenge of controlling phosphorus in chronic kidney disease. Nephrol Dial Transplant. 2016;31(4):541- 547. doi: 10.1093/ndt/gfv055..
DOI: 10.1093/ndt/gfv055

Hutchison A.J., Smith C.P., Brenchley P.E.C. Pharmacology, efficacy and safety of oral phosphate binders. Nat Rev Nephrol. 2011;7(10):578- 589. doi: 10.1038/nrneph.2011.112..
DOI: 10.1038/nrneph.2011.112

Jüppner H. Phosphate and FGF-23. Kidney Int Suppl. 2011;(121):24-27. doi: 10.1038/ ki.2011.27..
DOI: 10.1038/ ki.2011.27

Sigrist M., Bungay P., Taal M.W., McIntyre C.W. Vascular calcification and cardiovascular function in chronic kidney disease. Nephrol Dial Transplant. 2006;21(3):707-714. doi: 10.1093/ ndt/gfi236..
DOI: 10.1093/ ndt/gfi236

Бирагова М.С., Мартынов С.А., Грачева С.А. Нарушение фосфорно-кальциевого обмена у пациентов с сахарным диабетом и хронической болезнью почек. Сахарный диабет. 2012;(4):74-80. doi: 10.14341/2072-0351-5542. Biragova M.S., Gracheva S.A., Martynov S.A. Compromised calcium and phosphorus metabolism in patients with diabetes mellitus and chronic kidney disease. Sakharnyy diabet = Diabetes mellitus. 2012;(4):74-80. (In Russ.) doi: 10.14341/2072-0351-5542..
DOI: 10.14341/2072-0351-5542

Li X., Wang H.Y., Giachelli C.M. Role of sodiumdepended phosphate co-transporter, Pit-1, in vascular smooth muscle cell calcification. Circulation Research. 2006;(98):905–912. doi: 10.1161/01.RES.0000216409.20863.e7..
DOI: 10.1161/01.RES.0000216409.20863.e7

Cannata-Andia J.B., Roman-Garcia P., Hruska P. The connection between vascular calcification and bone health. Nephrol Dial Transplant. 2011;26(11):3429-3436. doi: 10.1093/ndt/ gfr591..
DOI: 10.1093/ndt/ gfr591

Dhingra D., Gona P., Benjamin E.J., Wang T.J., Aragam J., D’Agostino Sr., Kannel W.B., Vasan R.S. Relation of serum phosphorus levels to echocardiographic left ventricular mass and incidence of heart failure in community. Eur J Heart Fail. 2010;12(8):812-818. doi: 10.1093/ eurjhf/hfq106..
DOI: 10.1093/ eurjhf/hfq106

Block G.A., Hulbert-Shearon T.E., Levin N.W., Port F.K. Association of serum phosphorus and calcium x phosphate product with mortality risk in chronic hemodialysis patients: A national study. Am J Kidney Dis. 1998;31(4):607-617. doi: 10.1053/ajkd.1998.v31.pm9531176..
DOI: 10.1053/ajkd.1998.v31.pm9531176

Tonelli M., Sacks F., Pfeffer M., Gao Z., Curhan G. Cholesterol And Recurrent Events Trial Investigators.Relationship between serum phosphate level and cardiovascular event rate in people with coronary disease. Circulation. 2005;112(17):2627-2633. doi: 10.1161/ CIRCULATIONAHA.105.553198..
DOI: 10.1161/ CIRCULATIONAHA.105.553198

Foley R.N., Collins A.J., Herzog C.A., Ishani A., Kalra P.A. Serum phosphorus levels associate with coronary atherosclerosis in young adults. J Am Soc Nephrol. 2009;20(2):397-404. doi: 10.1681/ASN.2008020141..
DOI: 10.1681/ASN.2008020141

Kathryn L. Adeney, David S. Siscovick, Joachim H. Ix, Stephen L. Seliger, Michael G. Shlipak, Nancy S. Jenny, Bryan R. Kestenbaum. Association of serum phosphate with vascular and valvular calcification in moderate CKD. J Am Soc Nephrol. 2009;20(2):381–387. doi: 10.1681/ASN.2008040349..
DOI: 10.1681/ASN.2008040349

Chue C.D., Edwards N.C., Moody W.E., Steeds R.P., Townend J.N., Ferro C.J. Serum phosphate is associated with left ventricular mass in patients with chronic kidney disease: A cardiac magnetic resonance study. Heart. 2012;98(3):219-224. doi: 10.1136/ heartjnl-2011-300570..
DOI: 10.1136/ heartjnl-2011-300570

Foley R.N., Collins A.J., Herzog C.A., Ishani A., Kalra P.A. Serum phosphate and left ventricular hypertrophy in young adults: The coronary artery risk development in young adults study. Kidney Blood Press Res. 2009;32(1):37-44. doi: 10.1159/000203348..
DOI: 10.1159/000203348

Kestenbaum B., Sampson J.N., Rudser K.D., Patterson D.J., Seliger S.L., Young B., Sherrard D.J., Andress D.L. Serum phosphate level and mortality risk among people with chronic kidney disease. J Am Soc Nephrol. 2005;16(2):520- 528. doi: 10.1681/ASN.2004070602..
DOI: 10.1681/ASN.2004070602

Palmer S.C., Hayen A., Macaskill P., Pellegrini F., Craig J.C., Elder G.J., Strippoli G.F. Serum levels of phosphorus, parathyroid hormone, and calcium and risks of death and cardiovascular disease in individuals with chronic kidney disease: a systematic review and meta-analysis. JAMA. 2011;305(11):1119-27. doi: 10.1001/ jama.2011.308..
DOI: 10.1001/ jama.2011.308

Cannata-Andia J.B., Martin K.J. The challenge of controlling phosphorus in chronic kidney disease. Nephrol Dial Transplant. 2016;31(4):541-7. doi: 10.1093/ndt/gfv055..
DOI: 10.1093/ndt/gfv055

Beto J.A., Ramirez W.E., Bansal V.K. Medical nutrition therapy in adults with chronic kidney disease: integrating evidence and consensus into practice for the generalist registered rietitian Nutritionist. J Acad Nutr Diet. 2014;114(7):1077-87. doi: 10.1016/j.jand. 2013.12.009..
DOI: 10.1016/j.jand. 2013.12.009

Moe S.M., Zidehsarai M.P., Chambers M.A., Jackman L.A., Radcliffe J.S., Trevino L.L., Donahue S.E., Asplin J.R. Vegetarian compared with meat dietary protein source and phosphorus homeostasis in chronic kidney disease. Clin J Am Soc Nephrol. 2011;6(2):257-264. doi: 10.2215/CJN.05040610..
DOI: 10.2215/CJN.05040610

Chauveau P., Koppe L., Combe C., Lasseur C., Trolonge S., Aparicio M. Vegeterian diets and chronic kidney disease. Nephrol Dial Transplant. 2019;34(2):199-207. doi: 10.1093/ndt/gfy164..
DOI: 10.1093/ndt/gfy164

KDIGO 2017 Clinical Practice Guideline Update for the Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease–Mineral and Bone Disorder (CKD-MBD). Kidney Int Suppl (2011). 2017;7(1):1-59. doi: 10.1016/j. kisu.2017.04.001..
DOI: 10.1016/j. kisu.2017.04.001

Cannata-Andía J.B., Fernández-Martín J.L., Locatelli F., London G., Gorriz J.L., Floege J., Ketteler M., Ferreira A., Covic A., Rutkowski B., Memmos D., Bos W.J., Teplan V., Nagy J., Tielemans C., Verbeelen D., Goldsmith D., Kramar R., Martin P.Y., Wüthrich R.P., Pavlovic D., Benedik M., Sánchez J.E., Martínez-Camblor P., Naves-Díaz M., Carrero J.J., Zoccali C. Use of phosphate-binding agents is associated with a lower risk of mortality. Kidney Int. 2013;84(5):998-1008. doi: 10.1038/ki.2013.185..
DOI: 10.1038/ki.2013.185

Merjanian R., Budoff M., Adler S., Berman N., Mehrotra R. Coronary artery, aortic wall, and valvular calcification in nondialyzed individuals with type 2 diabetes and renal disease. Kidney Int. 2003;64(1):263-271. doi: 10.1046/j.1523-1755.2003.00068.x..
DOI: 10.1046/j.1523-1755.2003.00068.x

Chan S., Au K., Francis R., Made D.W., Johnson D.W., Pillars P. Phosphate binders in patients with chronic kidney disease Aust Prescr. 2017;40(1):10–14. doi: 10.18773/austprescr.2017.002..
DOI: 10.18773/austprescr.2017.002

Vervloet M.G., van Ballegooijen J. Prevention and treatment of hyperphosphatemia in chronic kidney disease. Kidney Int. 2018;93(5):1060- 1072. doi: 10.1016/j.kint.2017.11.036..
DOI: 10.1016/j.kint.2017.11.036

Мартынов С.А., Бирагова М.С., Шамхалова М.Ш., Шестакова М.В. Гиперфосфатемия при хронической болезни почек. Медицинский совет. 2013;(5-6):98-101. Режим доступа: https://elibrary.ru/item.asp?id=21168655. Martynov S.A., Biragova M.S., Shamkhalova M. Sh., Shestakova M.V. Hyperphosphatemia of chronic kidney disease. Meditsinskiy sovet = Medical Council. 2013;(5-6):98-101. (In Russ.) Available at: https://elibrary.ru/item. asp?id=21168655.https://elibrary.ru/item.asp?id=21168655

Мартынов С.А., Бирагова М.С., Шамхалова М.Ш., Шестакова М.В. Гиперфосфатемия при хронической болезни почек. Медицинский совет. 2013;(5-6):98-101. Режим доступа: https://elibrary.ru/item.asp?id=21168655. Martynov S.A., Biragova M.S., Shamkhalova M. Sh., Shestakova M.V. Hyperphosphatemia of chronic kidney disease. Meditsinskiy sovet = Medical Council. 2013;(5-6):98-101. (In Russ.) Available at: https://elibrary.ru/item. asp?id=21168655.https://elibrary.ru/item

Wills M.R., Savory J. Aluminium poisoning dialysis encephalopathy, osteomalacia, and anemia. Lancet. 1983;2(8340):29-34. doi: 10.1016/ s0140-6736(83)90014-4..
DOI: 10.1016/ s0140-6736(83)90014-4

Elder G.J., Center J. The role of calcium and non-calcium-based phosphate binders in cronic kidney disease. Nephrology (Carlton). 2017;22(Suppl 2):42-46. doi: 10.1111/ nep.13031..
DOI: 10.1111/ nep.13031

Burke S., Amin N., Incerti C., Plone M., Watson N. Sevelamer hydrochloride, a nonabsorbed phospaht-binding polymer, does not interfere with digoxin or warfarin pharmacokinetics. J Clin Pharmacol. 2001;41(2):193-198. doi: 10.1177/00912700122009872..
DOI: 10.1177/00912700122009872

Burke S., Amin N., Incerti C., Plone M., Lee J.W. Sevelamer hydrochloride, a phospaht-binding polymer, does not alter the pharmacokinetics of two commonly used antihypertensive in healthy volunteers. J Clin Pharmacol. 2001;(41):199-205. Available at: http://www. biomedsearch.com/nih/Sevelamerhydrochloride-Renagel-phosphate-binding/11210402.html.http://www

Chertow G.M., Burke S.K., Raggi P. Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients. Kidney Int. 2002;62(1):245-252. doi: 10.1046/j.1523-1755.2002.00434.x..
DOI: 10.1046/j.1523-1755.2002.00434.x

Othmane T.E.H., Bakonyi G., Egresits J. et al. Effect of sevelamer on aortic pulse wave velocity in patients on hemodialysis: A prospective observational study. Hemodial Int. 2007;11(Suppl 3):13-21. doi: 10.1111/j.1542-4758.2007.00224.x..
DOI: 10.1111/j.1542-4758.2007.00224.x

Takenaka T., Suzuki H. New strategy to attenuate pulse wave velocity in haemodialysis patients. Nephrol Dial Transplant. 2005;20:811– 816. doi: 10.1093/ndt/gfh656..
DOI: 10.1093/ndt/gfh656

Suki W.N., Zabaneh R., Cangiano J.L., Reed J., Fischer D., Garrett L., Ling B.N., Chasan-Taber S., Dillon M.A., Blair A.T., Burke S.K. Effects of sevelamer and calcium-based phosphate binders on mortality in hemodialysis patients. Kidney Int. 2007;72(9):1130-7. doi: 10.1038/sj. ki.5002466..
DOI: 10.1038/sj. ki.5002466

Block G.A., Raggi P., Bellasi A., Kooienga L., Spiegel D.M. Mortality effect of coronary calcification and phosphate binder choice in incident hemodialysis patients. Kidney Int. 2007;71(5):438-441. doi: 10.1038/sj.ki.5002059..
DOI: 10.1038/sj.ki.5002059

Di Iorio B., Molony D., Bell C., Cucciniello E., Bellizzi V., Russo D., Bellasi A; INDEPENDENT Study Investigators. Sevelamer versus calcium carbonate in incident hemodialysis patients: results of an open-label 24-month randomized clinical trial. Am J Kidney Dis. 2013;62(4):771- 778. doi: 10.1053/j.ajkd.2013.03.023..
DOI: 10.1053/j.ajkd.2013.03.023

Jamal S., Vandermeer B., Raggi P., Mendelssohn D.C., Chatterley T., Dorgan M., Lok C.E., Fitchett D. Effect of calcium-based versus non-calcium based phosphate binders on mortality in patients with chronic kidney disease: an updated systematic review and meta-analysis. Lancet. 2013;382(9900):1268-77. doi: 10.1016/S0140- 6736(13)60897-1..
DOI: 10.1016/S0140- 6736(13)60897-1

Patel L., Bernard L.M., Elder G. Sevelamer versus calcium based binders for treatment of hyperphosphatemia in CKD: a meta-analysis of randomized controlled trial. Clin J Am Soc Nephrol. 2016;11(2):232-44. doi: 10.2215/ CJN.06800615..
DOI: 10.2215/ CJN.06800615

de Francisco A.L., Leidig M., Covic A.C., Ketteler M., Benedyk-Lorens E., Mircescu G.M., Scholz C., Ponce P., Passlick-Deetjen J. Evaluation of calcium acetate/magnesium carbonate as a phosphate binder compared with sevelamer hydrochloride in haemodialysis patients: a controlled randomized study (CALMAG study) assessing efficacy and tolerability. Nephrol Dial Transplant. 2010;25(11):3707-3717. doi: 10.1093/ndt/gfq292..
DOI: 10.1093/ndt/gfq292

Covic A., Passlick-Deetjen J., Kroczak M., Büschges-Seraphin B., Ghenu A., Ponce P., Marzell B., de Francisco A.L. A comparison of calcium acetate/magnesium carbonate and sevelamer-hydrochloride effects on fibroblast growth factor-23 and bone markers: post hoc evaluation from a controlled, randomized study. Nephrol Dial Transplant. 2013;28(9):2383-2392. doi: 10.1093/ndt/gft203..
DOI: 10.1093/ndt/gft203

Torregrosa J.V., González-Parra E., González M.T., Cannata-Andía J. Rufus study: efficacy and safety of lanthanum carbonate in clinical practice in Spain. Nefrologia. 2014;34(3):360- 368. doi: 10.3265/Nefrologia.pre2014. Mar.12287..
DOI: 10.3265/Nefrologia.pre2014. Mar.12287

Shigematsu T., Tokumoto A., Nakaoka A., Arisaka H. Effect of lanthanum carbonate treatment on bone in Japanese dialysis patients with hyperphosphatemia. Ther Apher Dial. 2011;15(2):176- 84. doi: 10.1111/j.1744-9987.2010.00898.x..
DOI: 10.1111/j.1744-9987.2010.00898.x

Cernano V., Santoro D., Lacquaniti A., Constantino G., Visconti L., Buemi A., Buemi M. Phosphate binders for treatment of chronic kidney disease: role of iron oxyhydroxide. International Journal of Nephrology and Renovascular Disease. 2016;(9):11-19. doi: 10.2147/IJNRD.S78040..
DOI: 10.2147/IJNRD.S78040

Floege J., Covic A.C., Ketteler M., Rastogi A., Chong E.M., Gaillard S., Lisk L.J., Sprague S.M.; PA21 Study Group. A phase III study of the efficacy and safety of a novel iron-based phosphate binder in dialysis patients. Kidney Int. 2014;86(3):638-47. doi: 10.1038/ki.2014.58..
DOI: 10.1038/ki.2014.58

Язык текста: Русский

ISSN: 2079-701X